Articles related to BRAIN CANCER

The phase 2 trial provides evidence that dabrafenib combined with trametinib could serve as a more effective and safer first-line treatment option for pediatric low-grade gliomas with BRAF V600 mutations. Evaluate the data to consider how this may influence your treatment protocols.

Stay informed with the FDA’s latest update on temozolomide labeling, which includes new indications and safety guidelines crucial for treating specific brain tumors.

Exploring the power of focused ultrasound in disrupting the blood-brain barrier, Dr. Ahluwalia’s LIBERATE trial is set to revolutionize the treatment landscape for glioblastoma.

In this phase 3 nonrandomized controlled trial of 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) had a median OS of 19.3 months from randomization (22.4 months from surgery), while contemporaneous, matched external control patients receiving SOC had a median OS of 16.5 months from randomization; for patients with recurrent glioblastoma (rGBM), the median OS was 13.2 months from relapse in the DCVax-L group vs. 7.8 months in the external control cohort. Both in nGBM and rGBM, significant increases in the long-term tails of the survival curves were seen.

The FDA Oncologic Drugs Advisory Committee (ODAC) unanimously decided on October 28 that there is insufficient evidence to support the claim that the pediatric oncology drug 131-I-omburtamab improves overall survival. A radiolabeled antibody, 131-I-omburtamab was created to treat central nervous system/leptomeningeal (CNS/LM) metastases in pediatric patients with neuroblastoma.

There aren’t as many headlines concerning cell phones and brain cancer today, despite it formerly being a mainstay of frightened online fodder. Have people lost interest and simply unwilling to give up their phones? Have the studies on the topic allayed their concerns? Or is it that people just don’t believe cell phones are one of the numerous cancer hazards? Experts weigh in.